Supplemental material
Expert Review of Pharmacoeconomics & Outcomes Research
Volume 19, 2019 - Issue 5
Review
Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis
Zsombor ZrubkaDepartment of Health Economics, Corvinus University of Budapest, Budapest, Hungary;Doctoral School of Business and Management, Corvinus University of Budapest, Budapest, Hungary
https://orcid.org/0000-0002-1992-6087View further author information
https://orcid.org/0000-0002-1992-6087View further author information, László GulácsiDepartment of Health Economics, Corvinus University of Budapest, Budapest, HungaryCorrespondence[email protected]
https://orcid.org/0000-0002-9285-8746View further author information
https://orcid.org/0000-0002-9285-8746View further author information, Valentin BrodszkyDepartment of Health Economics, Corvinus University of Budapest, Budapest, Hungaryhttps://orcid.org/0000-0002-6095-2295View further author information
https://orcid.org/0000-0002-6095-2295View further author information, Fanni RenczDepartment of Health Economics, Corvinus University of Budapest, Budapest, Hungaryhttps://orcid.org/0000-0001-9674-620XView further author information
https://orcid.org/0000-0001-9674-620XView further author information, Rieke AltenRheumatology Research Center, Schlosspark-Klinik Charite, University Medicine Berlin, Berlin, Germanyhttps://orcid.org/0000-0002-3395-4412View further author information
https://orcid.org/0000-0002-3395-4412View further author information, Zoltán SzekaneczDivision of Rheumatology, Department of Medicine, University of Debrecen Faculty of Medicine, Debrecen, Hungaryhttps://orcid.org/0000-0002-7794-6844View further author information
https://orcid.org/0000-0002-7794-6844View further author information & Márta PéntekDepartment of Health Economics, Corvinus University of Budapest, Budapest, Hungary;Department of Rheumatology, Flór Ferenc County Hospital, Kistarcsa, Hungaryhttps://orcid.org/0000-0001-9636-6012View further author information
https://orcid.org/0000-0001-9636-6012View further author information show allRelated Research Data
Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis
Source:
Taylor & Francis
Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis
Source:
Taylor & Francis
Linking provided by
